ECSP22010121A - Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos - Google Patents
Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticosInfo
- Publication number
- ECSP22010121A ECSP22010121A ECSENADI202210121A ECDI202210121A ECSP22010121A EC SP22010121 A ECSP22010121 A EC SP22010121A EC SENADI202210121 A ECSENADI202210121 A EC SENADI202210121A EC DI202210121 A ECDI202210121 A EC DI202210121A EC SP22010121 A ECSP22010121 A EC SP22010121A
- Authority
- EC
- Ecuador
- Prior art keywords
- microtubule
- therapeutics
- targeting agents
- peptide conjugates
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a conjugados peptídicos de agentes dirigidos a microtúbulos tales como derivados de maitansinoide que son útiles para el tratamiento de enfermedades tal como cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962872638P | 2019-07-10 | 2019-07-10 | |
US202063041324P | 2020-06-19 | 2020-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22010121A true ECSP22010121A (es) | 2022-05-31 |
Family
ID=71944331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202210121A ECSP22010121A (es) | 2019-07-10 | 2022-02-09 | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11555019B2 (es) |
EP (1) | EP3996749A1 (es) |
JP (1) | JP2022541747A (es) |
KR (1) | KR20220051332A (es) |
CN (1) | CN114302744A (es) |
AU (1) | AU2020311925A1 (es) |
BR (1) | BR112022000297A2 (es) |
CA (1) | CA3146385A1 (es) |
CL (1) | CL2022000043A1 (es) |
CO (1) | CO2022001315A2 (es) |
CR (1) | CR20220057A (es) |
EC (1) | ECSP22010121A (es) |
IL (1) | IL289659A (es) |
MX (1) | MX2022000450A (es) |
PE (1) | PE20220485A1 (es) |
TW (1) | TW202116356A (es) |
WO (1) | WO2021007402A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
EP4274905A1 (en) | 2021-01-08 | 2023-11-15 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
TW202330015A (zh) * | 2021-11-17 | 2023-08-01 | 美商斯布雷克薩四號公司 | 作為治療劑之肽微管蛋白抑制劑之肽結合物 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
NZ313713A (en) | 1995-08-02 | 2001-03-30 | Univ Newcastle Ventures Ltd | Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors |
KR20000064811A (ko) | 1996-04-26 | 2000-11-06 | 스즈키 다다시 | 테트라히드로인돌리진 유도체의 제조법 |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
IN189180B (es) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
WO2000025825A1 (fr) | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Composes dds et procede de dosage de ces composes |
EP1391457B1 (de) | 1998-11-03 | 2013-12-25 | AbbVie Deutschland GmbH & Co KG | Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren |
JP4093448B2 (ja) | 1999-01-11 | 2008-06-04 | アグロン・ファーマシューティカルズ・インコーポレーテッド | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤 |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6699876B2 (en) | 1999-11-18 | 2004-03-02 | Les Laboratoires Servier | Camptothecin analogue compounds |
WO2001041534A2 (en) | 1999-12-13 | 2001-06-14 | Eli Lilly And Company | Pseudomycin phosphate prodrugs |
CA2401873A1 (en) * | 2000-03-15 | 2001-09-20 | Robert A. Copeland | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
AU2001271037A1 (en) | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
KR101003622B1 (ko) | 2002-03-01 | 2010-12-24 | 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 | 치료제 또는 세포독성제와 생물학적 활성 펩티드의컨쥬게이트 |
GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
ATE491703T1 (de) | 2002-04-30 | 2011-01-15 | Kudos Pharm Ltd | Phthalazinonderivate |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP2006522088A (ja) | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
EA009285B1 (ru) | 2003-05-14 | 2007-12-28 | Иммуноджен, Инк. | Композиция конъюгированного лекарственного средства |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
LT3524611T (lt) | 2003-05-20 | 2021-04-12 | Immunogen, Inc. | Patobulinti citotoksiniai agentai, apimantys naujus maitansinoidus |
ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CA2547077C (en) | 2003-12-01 | 2015-11-03 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
KR100876520B1 (ko) | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(adp-리보오스) 폴리머라제 억제제의 제조 방법 |
EP1799685B1 (en) | 2004-09-22 | 2012-03-28 | Pfizer Inc. | Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
CA2581200A1 (en) | 2004-09-22 | 2006-03-30 | Pfizer Inc. | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
EP1819359B1 (en) | 2004-12-09 | 2015-03-18 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods of their production and their use |
EP1846014B1 (en) | 2005-01-18 | 2012-10-24 | The Board of Governors for Higher Education State of Rhode Island and Providence Plantations | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide |
US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
CN102603770A (zh) | 2005-04-15 | 2012-07-25 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
BRPI0615049B1 (pt) | 2005-08-24 | 2023-04-25 | Immunogen, Inc | Processo para a preparação de um conjugado de anticorpo- maitansinóide |
EP1957477B1 (en) | 2005-09-29 | 2011-12-07 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
DK1945647T3 (da) | 2005-11-08 | 2012-05-07 | Immunogen Inc | Fremgangsmåder til fremstilling af maytansinol |
US20070265324A1 (en) | 2006-01-17 | 2007-11-15 | Wolfgang Wernet | Combination Therapy with Parp Inhibitors |
TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
MX2009007200A (es) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). |
WO2008114114A2 (en) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
EP3858347A3 (en) | 2007-08-17 | 2021-12-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
DK2437790T3 (da) | 2009-06-03 | 2019-05-20 | Immunogen Inc | Konjugeringsfremgangsmåder |
US9353140B2 (en) | 2009-11-25 | 2016-05-31 | Academia Sinica | BQC-G, a tumor-selective anti-cancer prodrug |
RS55487B1 (sr) | 2010-02-12 | 2017-04-28 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
CA2790577A1 (en) | 2010-02-25 | 2011-09-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
EP4098272A3 (en) | 2010-07-13 | 2023-03-08 | University of Rhode Island Board of Trustees | Compositions comprising a ph-sensitive membrane insertion polipeptide |
US8846081B2 (en) | 2010-08-13 | 2014-09-30 | Rhode Island Board Of Governors For Higher Education | Liposome compositions and methods of use thereof |
AU2011323316B2 (en) | 2010-11-03 | 2016-02-25 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
US8795673B2 (en) | 2011-03-29 | 2014-08-05 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
WO2012135517A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
KR102584005B1 (ko) | 2012-10-11 | 2023-09-27 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
US9180203B2 (en) | 2012-10-23 | 2015-11-10 | The Johns Hopkins University | Self-assembling drug amphiphiles and methods for synthesis and use |
WO2014093343A2 (en) | 2012-12-10 | 2014-06-19 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
IL290330B2 (en) | 2013-12-19 | 2023-09-01 | Seagen Inc | Methylene carbamate binders for use with drug-targeting conjugates |
EP3094752A4 (en) | 2014-01-16 | 2017-08-16 | Clovis Oncology, Inc. | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
ES2859648T3 (es) | 2014-04-10 | 2021-10-04 | Daiichi Sankyo Co Ltd | Conjugado anticuerpo-fármaco anti-HER3 |
WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
EP3110447B1 (en) | 2014-09-16 | 2020-04-29 | Synermore Biologics Co., Ltd. | Anti-egfr antibody and uses of same |
SG11201703599VA (en) | 2014-11-19 | 2017-06-29 | Immunogen Inc | Process for preparing cell-binding agent-cytotoxic agent conjugates |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
ME03757B (me) | 2015-11-24 | 2021-04-20 | Theravance Biopharma R&D Ip Llc | Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti |
KR102498258B1 (ko) | 2016-01-20 | 2023-02-10 | 삼성디스플레이 주식회사 | 표시 장치 |
US20170267727A1 (en) | 2016-03-04 | 2017-09-21 | Lehigh University | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors |
EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
EP3442592A4 (en) | 2016-04-13 | 2019-11-27 | Tarveda Therapeutics, Inc. | NEUROTENSIN RECEPTOR BINDING CONJUGATES AND ASSOCIATED FORMULATIONS |
GB201608885D0 (en) | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
WO2017210608A1 (en) | 2016-06-02 | 2017-12-07 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
CA3032401A1 (en) * | 2016-07-29 | 2018-02-01 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
AU2017311927B2 (en) | 2016-08-16 | 2021-06-03 | National Institute Of Advanced Industrial Science And Technology | Malignant tumor target peptide |
CA3037241A1 (en) * | 2016-09-22 | 2018-03-29 | Rhode Island Council On Postsecondary Education | Fluorescent compound comprising a fluorophore conjugated to a ph-triggered polypeptide |
CA3066384A1 (en) | 2017-06-09 | 2018-12-13 | Rhode Island Council On Postsecondary Education | Linked and other ph-triggered compounds |
CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
CR20200334A (es) | 2018-01-05 | 2021-03-09 | Cybrexa 1 Inc | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas |
MX2020007442A (es) | 2018-01-12 | 2020-09-14 | Prolynx Llc | Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion. |
EP4257611A3 (en) | 2018-05-18 | 2024-03-06 | Glycotope GmbH | Anti-muc1 antibody |
TW202015740A (zh) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
CN109232719B (zh) | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
WO2020160009A1 (en) * | 2019-01-28 | 2020-08-06 | Rhode Island Council On Postsecondary Education | Phlip® targeted delivery of potent cytotoxic compounds |
PT3946464T (pt) | 2019-03-29 | 2022-11-16 | Medimmune Ltd | Compostos e seus conjugados |
KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
-
2020
- 2020-07-09 JP JP2022501186A patent/JP2022541747A/ja active Pending
- 2020-07-09 MX MX2022000450A patent/MX2022000450A/es unknown
- 2020-07-09 US US16/924,445 patent/US11555019B2/en active Active
- 2020-07-09 CN CN202080057629.3A patent/CN114302744A/zh active Pending
- 2020-07-09 KR KR1020227004520A patent/KR20220051332A/ko unknown
- 2020-07-09 EP EP20750936.5A patent/EP3996749A1/en active Pending
- 2020-07-09 TW TW109123266A patent/TW202116356A/zh unknown
- 2020-07-09 PE PE2022000038A patent/PE20220485A1/es unknown
- 2020-07-09 CA CA3146385A patent/CA3146385A1/en active Pending
- 2020-07-09 BR BR112022000297A patent/BR112022000297A2/pt unknown
- 2020-07-09 CR CR20220057A patent/CR20220057A/es unknown
- 2020-07-09 WO PCT/US2020/041348 patent/WO2021007402A1/en unknown
- 2020-07-09 AU AU2020311925A patent/AU2020311925A1/en active Pending
-
2022
- 2022-01-06 IL IL289659A patent/IL289659A/en unknown
- 2022-01-07 CL CL2022000043A patent/CL2022000043A1/es unknown
- 2022-02-09 CO CONC2022/0001315A patent/CO2022001315A2/es unknown
- 2022-02-09 EC ECSENADI202210121A patent/ECSP22010121A/es unknown
-
2023
- 2023-01-11 US US18/152,987 patent/US20240067616A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20220485A1 (es) | 2022-04-04 |
CN114302744A (zh) | 2022-04-08 |
CA3146385A1 (en) | 2021-01-14 |
CR20220057A (es) | 2022-07-19 |
EP3996749A1 (en) | 2022-05-18 |
AU2020311925A1 (en) | 2022-02-03 |
TW202116356A (zh) | 2021-05-01 |
IL289659A (en) | 2022-03-01 |
CO2022001315A2 (es) | 2022-05-10 |
US20240067616A1 (en) | 2024-02-29 |
CL2022000043A1 (es) | 2022-08-19 |
US20210009536A1 (en) | 2021-01-14 |
MX2022000450A (es) | 2022-04-25 |
BR112022000297A2 (pt) | 2022-03-15 |
JP2022541747A (ja) | 2022-09-27 |
KR20220051332A (ko) | 2022-04-26 |
WO2021007402A1 (en) | 2021-01-14 |
US11555019B2 (en) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022001316A2 (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
ECSP22010121A (es) | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos | |
CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
BR112021024830A2 (pt) | Vesículas extracelulares microbianas processadas | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CO2022004694A2 (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
UY36075A (es) | Derivados de tubulisina | |
ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
AR104987A1 (es) | Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos | |
SV2019005822A (es) | Metodos para tratar el cáncer de próstata | |
CO2020000227A2 (es) | Moduladores de nlrp3 | |
ECSP22007981A (es) | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
CO2020016131A2 (es) | Agonistas de tlr7 | |
MX2020004678A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
CL2018002368A1 (es) | Formulaciones de oritavancina | |
CL2018000726A1 (es) | Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1 | |
BR112022022590A2 (pt) | Formulações farmacêuticas de acetato de abiraterona e niraparibe | |
AR120058A1 (es) | Vesículas extracelulares microbianas procesadas |